Reported Sunday, Mesoblast Completes Patient Treatment In Pivotal Phase 3 MSB-DR004 Trial Of Rexlemestrocel-L For Chronic Low Back Pain, Enrolling 350 Patients

Piper Sandler Reiterates Overweight on Mesoblast, Raises Price Target to $39

Piper Sandler analyst Edward Tenthoff reiterates Mesoblast (NASDAQ:MESO) with a Overweight and raises the price target from $35 to $39.

Mesoblast shares are trading higher after the company reported better-than-expected FY sales results.

Mesoblast FY EPS $(0.04) Misses $0.01 Estimate, Sales $120.250M Beat $66.000M Estimate

Mesoblast (NASDAQ:MESO) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $0.01 by 500 percent. This is a 50 percent increase over losses of $(0.09) per share from the same

Mesoblast Reports Substantial Revenue Growth to US$120M

Mesoblast Limited reported strong financial results for FY2026 with total revenue of US$120.3 million, driven by successful RYONCIL commercial launch generating US$115.2 million in net revenue. The company completed patient treatment in its Phase 3 trial for chronic low back pain (rexlemestrocel-L), with results expected mid-2027. Net losses were reduced 44% to US$57.5 million. The company is expanding RYONCIL into adult markets and developing next-generation CAR-MSC and oncolytic virus technologies.